Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Mov Disord ; 35(2): 316-325, 2020 02.
Artigo em Inglês | MEDLINE | ID: mdl-31710401

RESUMO

BACKGROUND: Impulse control disorders related to alterations in the mesocorticolimbic dopamine network occur in Parkinson's disease (PD). Our objective was to investigate the functional neural substrates of reward processing and inhibitory control in these patients. METHODS: Eighteen PD patients with impulse control disorders, 17 without this complication, and 18 healthy controls performed a version of the Iowa Gambling Task during functional magnetic resonance scanning under 3 conditions: positive, negative, and mixed feedback. Whole-brain contrasts, regions of interest, time courses, functional connectivity analyses, and brain-behavior associations were examined. RESULTS: PD patients with impulse control disorders exhibited hyperactivation in subcortical and cortical regions typically associated with reward processing and inhibitory control compared with their PD and healthy control counterparts. Time-course analyses revealed that only PD patients with impulse control disorders exhibited stronger signal intensity during the initial versus final periods of the negative-feedback condition in bilateral insula, and right ventral striatum. Interestingly, hyperactivation of all the examined right-lateralized frontostriatal areas during negative feedback was positively associated with impulse control disorder severity. Importantly, positive associations between impulse control disorder severity and regional activations in the right insula and right inferior frontal gyrus, but not the right subthalamic nucleus, were mediated by functional connectivity with the right ventral striatum. CONCLUSIONS: During a reward-based task, PD patients with impulse control disorders showed hyperactivation in a right-lateralized network of regions including the subthalamic nucleus that was strongly associated with impulse control disorder severity. In these patients, the right ventral striatum in particular played a critical role in modulating the functional dynamics of right-lateralized inhibitory-control frontal regions when facing penalties. © 2019 International Parkinson and Movement Disorder Society.


Assuntos
Encéfalo/fisiopatologia , Transtornos Disruptivos, de Controle do Impulso e da Conduta/psicologia , Inibição Neural/fisiologia , Doença de Parkinson/psicologia , Adulto , Idoso , Transtornos Disruptivos, de Controle do Impulso e da Conduta/etiologia , Feminino , Jogo de Azar/complicações , Humanos , Imageamento por Ressonância Magnética/métodos , Masculino , Pessoa de Meia-Idade , Testes Neuropsicológicos , Doença de Parkinson/complicações , Recompensa
2.
Eur J Nucl Med Mol Imaging ; 46(10): 2065-2076, 2019 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-31273436

RESUMO

PURPOSE: Previous studies in patients with Parkinson's disease (PD) and impulse control disorders (ICDs) have produced heterogeneous results regarding striatal dopamine transporter (DaT) binding and activity in the mesocorticolimbic network. Our aim here was to study the relationship between striatal DaT availability and cortical metabolism, as well as motor, behavioural and cognitive features of PD patients with ICD. METHODS: In a group of PD patients with ICD (PD-ICD, n = 16) and 16 matched PD patients without ICD (PD-noICD, n = 16), DaT single-photon emission computed tomography (SPECT) imaging (DaTSCAN) was used to study DaT availability in predefined striatal volumes of interest (VOIs): putamen, caudate nucleus and ventral striatum (VS). In addition, the specific association of striatal DaT binding with cortical limbic and associative metabolic activity was evaluated by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in PD-ICD patients and investigated using statistical parametric mapping (SPM8). Finally, associations between DaT availability and motor, behavioural and cognitive features were assessed. RESULTS: PD-ICD patients had a significantly lower DaT density in the VS than PD-noICD patients, which was inversely associated with ICD severity. Lower DaT availability in the VS was associated with lower FDG uptake in several cortical areas belonging to the limbic and associative circuits, and in other regions involved in reward and inhibition processes (p < 0.0001 uncorrected; k > 50 voxels). No significant results were observed using a higher conservative threshold (p < 0.05; FDR corrected). PD-ICD patients also displayed impairment in interference and attentional Stroop Task execution, and more anxiety, all associated with reduced DaT availability in the VS and caudate nucleus. CONCLUSIONS: ICDs in PD patients are related to reduced DaT binding in the VS, which accounts for dysfunction in a complex cortico-subcortical network that involves areas of the mesolimbic and mesocortical systems, being associated with reward evaluation, salience attribution and inhibitory control processes.


Assuntos
Corpo Estriado/diagnóstico por imagem , Transtornos Disruptivos, de Controle do Impulso e da Conduta/diagnóstico por imagem , Proteínas da Membrana Plasmática de Transporte de Dopamina/metabolismo , Doença de Parkinson/diagnóstico por imagem , Substância Negra/diagnóstico por imagem , Idoso , Corpo Estriado/metabolismo , Transtornos Disruptivos, de Controle do Impulso e da Conduta/complicações , Transtornos Disruptivos, de Controle do Impulso e da Conduta/metabolismo , Transtornos Disruptivos, de Controle do Impulso e da Conduta/patologia , Feminino , Fluordesoxiglucose F18 , Humanos , Masculino , Pessoa de Meia-Idade , Doença de Parkinson/complicações , Doença de Parkinson/metabolismo , Doença de Parkinson/patologia , Tomografia por Emissão de Pósitrons , Compostos Radiofarmacêuticos , Substância Negra/metabolismo , Tomografia Computadorizada de Emissão de Fóton Único
3.
Clin Exp Rheumatol ; 32(2): 275-84, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24321604

RESUMO

Neurologic manifestations are found in 5-15 % of patients with sarcoidosis. This granulomatous disease may affect any part of the peripheral or the central nervous system, being potentially severe and difficult to treat. Corticosteroids are the cornerstone of therapy in sarcoidosis. However, some patients become resistant or experience side effects to corticosteroids. In these patients, second line therapies including immunosuppressive drugs such as methotrexate, azathioprine, mycophenolate, cyclophosphamide and leflunomide have been used. Anti-TNF-α drugs have been proposed as a therapeutic option for those who are refractory to immunosuppressive drugs or initially in cases of severe sarcoidosis. We report on 5 patients with neurosarcoidosis treated with anti-TNF-α drugs in our center. A literature review of patients with neurosarcoidosis treated with anti-TNF-α drugs was conducted. In our series successful response to anti-TNF-α therapy was achieved. However, the high frequency of relapses following anti-TNF-α discontinuation makes necessary a close follow-up of these patients when the biologic agent is stopped.


Assuntos
Doenças do Sistema Nervoso Central , Imunossupressores , Sarcoidose , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Corticosteroides/administração & dosagem , Corticosteroides/efeitos adversos , Adulto , Idoso , Biópsia , Doenças do Sistema Nervoso Central/diagnóstico , Doenças do Sistema Nervoso Central/tratamento farmacológico , Doenças do Sistema Nervoso Central/imunologia , Doenças do Sistema Nervoso Central/fisiopatologia , Resistência a Medicamentos , Feminino , Granuloma/imunologia , Granuloma/patologia , Humanos , Imunossupressores/administração & dosagem , Imunossupressores/efeitos adversos , Imunossupressores/classificação , Linfonodos/patologia , Masculino , Pessoa de Meia-Idade , Sarcoidose/diagnóstico , Sarcoidose/tratamento farmacológico , Sarcoidose/imunologia , Sarcoidose/fisiopatologia , Prevenção Secundária , Resultado do Tratamento , Fator de Necrose Tumoral alfa/imunologia
4.
Rev. clín. esp. (Ed. impr.) ; 213(7): e67-70, oct. 2013.
Artigo em Espanhol | IBECS | ID: ibc-115619

RESUMO

La apoplejía pituitaria (AP) es una enfermedad potencialmente mortal causada por infarto isquémico o hemorragia aguda de un adenoma hipofisario. Aunque normalmente hay paresia oculomotora, la oftalmoplejía completa es una forma rara de presentación, más aún si la función visual está respetada. Un varón de 70 años se presentó con cefalea retroorbitaria y oftalmoplejía progresiva completa derecha con agudeza visual preservada. Una RMN reveló una masa hipofisaria con focos hiperintensos en T1 y realce tras la administración de gadolinio que se extendía hacia ambos senos cavernosos. Los análisis demostraron una insuficiencia hipofisaria parcial. Se inició tratamiento sustitutivo con corticoides antes de una resección transesfenoidal de la masa. El examen anatomopatológico era compatible con un adenoma hipofisario. Una semana tras la intervención, quedaba una leve limitación para la abducción del ojo derecho. La AP debería tenerse en cuenta en los pacientes con oftalmoplejía y cefalea retroorbitaria aguda. Es necesaria una aproximación multidisciplinar para resolver la disfunción hormonal y preservar la función visual (AU)


Pituitary apoplexy (PA) is a potentially life-threatening disorder caused by acute ischemic infarction or haemorrhage of a pituitary adenoma. Although certain degree of ocular palsy is usually present, total ophthalmoplegia is an uncommon form of presentation, moreover with spared visual acuity. We report the case of a 70-year-old man who presented with retro-orbitary headache and progressive total right ophthalmoplegia with preserved visual function. MRI study revealed a pituitary mass with hyperintense T1 foci inside and postgadolinium enhancement that extended towards both cavernous sinuses. Laboratory tests showed a partial pituitary failure. Corticosteroid replacement was started before a trans-sphenoidal resection of the mass was done. Histopathology analysis was consistent with a pituitary adenoma. One week after intervention only a subtle defect for abduction of the right eye was present. PA should be considered when attending patients with ophthalmoplegia, and acute retroocular headache. A multidisciplinary approach must be rapidly done in order to solve hormonal dysfunction and preserve visual function (AU)


Assuntos
Humanos , Masculino , Pessoa de Meia-Idade , Oftalmoplegia/complicações , Oftalmoplegia/diagnóstico , Oftalmoplegia/terapia , Apoplexia Hipofisária/complicações , Apoplexia Hipofisária/diagnóstico , Cefaleia/complicações , Cefaleia/diagnóstico , Acuidade Visual , Acuidade Visual/efeitos da radiação , Corticosteroides/uso terapêutico , Oftalmoplegia/fisiopatologia , Oftalmoplegia , Gadolínio , Imageamento por Ressonância Magnética/métodos , Imageamento por Ressonância Magnética
6.
Int J STD AIDS ; 24(1): 39-41, 2013 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23467294

RESUMO

Although peripheral facial palsy is the most common cranial neuropathy in HIV-infected patients, no series have been reported recently in the literature. In this study we reviewed the clinical records of HIV-infected patients with a diagnosis of peripheral facial palsy between 2000 and 2011 attending the Hospital Marqués de Valdecilla (Infectious Diseases Unit), a 900-bed university hospital in northern Spain. We identified eight patients (4 men, 4 women): median CD4 count and viral load were 232 cells per µL and 130,000 RNA copies per mL, respectively. Most of them presented co-morbidities, including hepatitis C virus in 75%, hepatitis B virus in 15% and tuberculosis in 15%. Aetiologies of palsy were varied: idiopathic Bell's palsy predominated at early stages of the disease, whereas secondary causes, such as lymphoma and infections were frequently the cause of paralysis in advanced HIV/AIDS. At early stages of HIV infection, facial palsy is similar, both in aetiology and prognosis, to cases in the general population. However, in advanced stages the palsy is frequently secondary to underlying complications. Clinicians should be aware of these differences to tailor the diagnostic work-up.


Assuntos
Paralisia Facial/complicações , Infecções por HIV/complicações , Corticosteroides/uso terapêutico , Adulto , Antivirais/uso terapêutico , Contagem de Linfócito CD4 , Comorbidade , Paralisia Facial/epidemiologia , Paralisia Facial/etiologia , Feminino , Infecções por HIV/tratamento farmacológico , Infecções por HIV/epidemiologia , Infecções por HIV/virologia , Hepatite B/tratamento farmacológico , Hepatite B/epidemiologia , Hepatite C/tratamento farmacológico , Hepatite C/epidemiologia , Hospitais Universitários , Humanos , Masculino , Índice de Gravidade de Doença , Espanha/epidemiologia , Resultado do Tratamento , Tuberculose/epidemiologia , Carga Viral
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA